Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 May;48(1):35-9.
doi: 10.1016/j.ymeth.2009.02.008. Epub 2009 Feb 24.

DNA-lesion mapping in mammalian cells

Affiliations

DNA-lesion mapping in mammalian cells

Ahmad Besaratinia et al. Methods. 2009 May.

Abstract

Formation of DNA damage is a crucial event in carcinogenesis. Irreparable DNA lesions have the potential to cause mispairing during DNA replication, thereby giving rise to mutations. Critically important mutations in cancer-related genes, i.e., oncogenes and tumor suppressor genes, are key contributors to carcinogenesis. Theoretically, co-localization(s) of persistent DNA lesions and mutational hotspots in cancer-relevant genes can be used for causality inference. The inferred causality can be validated if a suspected carcinogen can similarly produce corresponding patterns of DNA damage and mutagenesis in vitro and/or in vivo. DNA-lesion footprinting (mapping) in conjunction with mutagenicity analysis is used for investigating cancer etiology. Ligation-mediated polymerase chain reaction (LM-PCR) is a versatile DNA-lesion footprinting technique, which enables sensitive and specific detection of DNA damage, at the level of nucleotide resolution, in genomic DNA. Here, we describe an updated protocol for LM-PCR analysis of the mammalian genome. This protocol can routinely be used for DNA-lesion footprinting of a variety of chemical and/or physical carcinogens in mammalian cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1. (a) Mutation spectrum and (b) codon distribution of the TP53 tumor suppressor gene in human non-melanoma skin tumors (basal cell and squamous cell carcinomas; n = 541)
Data were obtained from the TP53 mutation database of the International Agency for Research on Cancer (R12 version) (31). Ins: Insertions; Del: Deletions.
Figure 1
Figure 1. (a) Mutation spectrum and (b) codon distribution of the TP53 tumor suppressor gene in human non-melanoma skin tumors (basal cell and squamous cell carcinomas; n = 541)
Data were obtained from the TP53 mutation database of the International Agency for Research on Cancer (R12 version) (31). Ins: Insertions; Del: Deletions.
Figure 2
Figure 2. A schematic outline of the LM-PCR procedure
A lesion in the original DNA is indicated by ◆. P1, P2, and P3 indicate gene-specific Primers 1, 2, and 3, respectively.
Figure 3
Figure 3. LM-PCR with Maxam and Gilbert chemical reactions
Genomic DNA of Big Blue® mouse embryonic fibroblasts was subjected to standard Maxam and Gilbert chemical reactions (20, 21), and subsequently LM-PCR was performed on the cII transgene. Individual Maxam/Gilbert sequencing ladders include “G”, “G + A”, “C”, and “C + T”. M = Molecular weight standard marker.

References

    1. Besaratinia A, Pfeifer GP. Carcinogenesis. 2006;27:1526–37. - PubMed
    1. Denissenko MF, Pao A, Tang M, Pfeifer GP. Science. 1996;274:430–32. - PubMed
    1. Becker MM, Wang Z, Grossmann G, Becherer KA. Proc Natl Acad Sci U S A. 1989;86:5315–19. - PMC - PubMed
    1. Chen JX, Zheng Y, West M, Tang MS. Cancer Res. 1998;58:2070–75. - PubMed
    1. DeMarini DM, Landi S, Tian D, Hanley NM, Li X, Hu F, Roop BC, Mass MJ, Keohavong P, Gao W, Olivier M, Hainaut P, Mumford JL. Cancer Res. 2001;61:6679–81. - PubMed

Publication types

MeSH terms

LinkOut - more resources